- Conditions
- COVID-19
- Interventions
- Self-Benefit/Social Norm, Self-Benefit/No Social Norm, Other Benefit/Social Norm, Other Benefit/No Social Norm
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 16,903 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 205
matching trials from the live ClinicalTrials.gov search.
- Conditions
- End Stage Kidney Disease, Depressive Symptoms
- Interventions
- Joviality(TM), Inert Virtual Reality
- Behavioral · Other
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Chicago, Illinois
- Conditions
- B-Cell Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
- Conditions
- LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
- Interventions
- DR-01
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Irvine, California + 11 more
- Conditions
- Sexually Transmitted Diseases, HIV
- Interventions
- Pre Exposure Prophylaxis, Characteristics of women who enroll, referral sources of women who enroll
- Other · Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Embosphere Microspheres, HoLEP Procedure
- Device · Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Mature B-Cell Malignancies
- Interventions
- Sonrotoclax, Zanubrutinib, Obinutuzumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 9 more
- Conditions
- Fabry's Disease
- Interventions
- Smartpill, Endoscopic Mucosal Resection
- Device · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
- Interventions
- Iomab-B, CAR-T cell
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter Transformation
- Interventions
- Tacabrutideg
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 26 more
- Conditions
- Multiple Sclerosis
- Interventions
- Aerobic exercise, Stretching and toning exercise
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- CD20-positive B-cell Non-Hodgkin Lymphoma
- Interventions
- Part 1, Cohort 1, Part 1, Cohort 2, Part 1, Cohort 3, Part 2, Cohort 1, Part 2, Cohort 2
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- New York, New York • Rochester, New York • Nashville, Tennessee + 1 more
- Conditions
- Smoking
- Interventions
- Enhanced Care, TAU
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Large B-Cell Lymphoma
- Interventions
- Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 60
- States / cities
- Anchorage, Alaska • Anaheim, California • Clovis, California + 49 more
- Conditions
- Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Interventions
- Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin, Irinotecan (drug), Topotecan
- Drug
- Lead sponsor
- Phanes Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 11 more
- Conditions
- Opioid-use Disorder, Amphetamine Use Disorders
- Interventions
- Neurocognitive Empowerment for Addiction Treatment (NEAT), Active Control
- Behavioral
- Lead sponsor
- Laureate Institute for Brain Research, Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Major Depressive Disorder
- Interventions
- FMRI with sham controlled feedback, FMRI with real time feedback
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Obesity, Stroke
- Interventions
- Lifestyle Management Program, Post-stroke Optimization of Walking using Explosive Resistance
- Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
- Interventions
- ARV-393, Glofitamab
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- New Haven, Connecticut • Miami, Florida • Detroit, Michigan + 6 more
- Conditions
- Type 2 Diabetes
- Interventions
- Roux-en-Y Gastric Bypass, Laparoscopic adjustable gastric banding, Vertical Sleeve Gastrectomy
- Procedure
- Lead sponsor
- Blandine Laferrere
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Eating Behavior
- Interventions
- Sequential Variety, Simultaneous Variety, Single Food, Small portion, Large Portion
- Other
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 20 Years to 65 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Diffuse Large-cell B-cell Lymphoma
- Interventions
- Plamotamab, Tafasitamab, Lenalidomide
- Biological · Drug
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Blinatumomab, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Charleston, South Carolina • Greenville, South Carolina
- Conditions
- Obesity
- Interventions
- Flexible Sigmoidoscopy
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota